Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • Log out
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Pathophysiology/Complications

The BIGTT Test

A novel test for simultaneous measurement of pancreatic β-cell function, insulin sensitivity, and glucose tolerance

  1. Torben Hansen, MD, PHD1,
  2. Thomas Drivsholm, MD, PHD2,
  3. Søren A. Urhammer, MD, DMSCI1,
  4. Rene T. Palacios, MSCI3,
  5. Aage Vølund, MSCI3,
  6. Knut Borch-Johnsen, MD, DMSCI12 and
  7. Oluf Pedersen, MD, DMSCI1
  1. 1Steno Diabetes Center, Copenhagen, Denmark
  2. 2Research Centre for Prevention and Health, Glostrup University Hospital, Glostrup, Denmark
  3. 3Department of Biostatistics, Novo Nordisk, Copenhagen, Denmark
  1. Address correspondence and reprint requests to Torben Hansen, MD, PhD, Steno Diabetes Center, Niels Steensens Vej 2, DK-2820 Gentofte, Denmark. E-mail: toha{at}steno.dk
Diabetes Care 2007 Feb; 30(2): 257-262. https://doi.org/10.2337/dc06-1240
PreviousNext
  • Article
  • Figures & Tables
  • Suppl Material
  • Info & Metrics
  • PDF
Loading

A novel test for simultaneous measurement of pancreatic β-cell function, insulin sensitivity, and glucose tolerance

Abstract

OBJECTIVE—Insulin resistance and impaired β-cell function are key elements in the pathogenesis of type 2 diabetes. We aimed to develop valid algorithms for estimation of the insulin sensitivity index (SI) and acute insulin response (AIR) derived from simple and cheap physiological measurements that could be used in large-scale metabolic, genetic, and epidemiological studies.

RESEARCH DESIGN AND METHODS—For our purpose, data from an oral glucose tolerance test (OGTT) (18 samples during 240 min) and a tolbutamide-modified intravenous glucose tolerance test (IVGTT) (33 samples during 180 min) from 258 individuals with fasting plasma glucose <7 mmol/l and 2-h plasma glucose <7.8 mmol/l were used for model development and internal validation. Data from an additional 28 individuals were used for external validation. Bergman’s minimal model was used to calculate SI, and the trapezoidal method was used to calculate AIR0–8 min. Multiple linear regression was applied to derive predictive equations of log(SI) and log(AIR0–8 min) using data on sex, BMI, plasma glucose, and serum insulin levels obtained during the OGTT.

RESULTS—We demonstrate that it is possible to obtain estimates of SI (BIGTT-SI) and AIR (BIGTT-AIR) that are highly correlated to IVGTT-derived values of SI (R2 = 0.77) and AIR (R2 = 0.54). In the two validation datasets we obtained similar results.

CONCLUSIONS—Data from OGTTs can provide accurate measures of insulin sensitivity and β-cell function, which can be used in large scale metabolic, genetic, and epidemiological studies.

  • AIR, acute insulin response
  • HOMA, homeostasis model assessment
  • IGT, impaired glucose tolerance
  • IVGTT, intravenous glucose tolerance test
  • OGTT, oral glucose tolerance test
  • RCPH, Research Centre for Prevention and Health

The maintenance of normal glucose homeostasis involves the simultaneous and coordinated roles of insulin release from the pancreatic β-cells and insulin action on peripheral tissues, primarily muscle (1,2). For estimation of whole-body insulin sensitivity, the euglycemic-hyperinsulinemic clamp is considered the “gold standard” (3). The assessment of the insulin sensitivity index (SI) by the minimal model for the intravenous glucose tolerance test (IVGTT) has also been used in numerous studies (4), because the method has the advantage of providing simultaneous information on the SI and acute insulin response (AIR). Both methods are considered to provide exact and, among individuals with normal glucose tolerance, comparable measurements of insulin sensitivity (5). However, because these methods are time consuming and expensive and cannot be performed on the same day as an oral glucose tolerance test (OGTT), neither is suitable for large-scale studies.

In the present study, we examine nondiabetic individuals without impaired glucose tolerance (IGT) to derive equations that are more accurate than those currently available for the SI and the AIR from an OGTT (1,6–12). We have used detailed information from both plasma glucose and serum insulin levels during an extended and frequently sampled OGTT combined with information on anthropometric measures and sex to generate equations and data from a frequently sampled IVGTT performed in the same individuals as reference. The approach is empirical and data driven, with multiple regression statistics being applied to the physiological data obtained.

RESEARCH DESIGN AND METHODS

Individuals for model development and internal validation

OGTT data from 258 individuals with fasting plasma glucose <7.0 mmol/l and 2-h plasma glucose <7.8 mmol/l (nondiabetic without IGT) were used to develop (75% of the data) and validate (25% of the data) models. All participants were from 1 of 60 families as described previously (13). The performance of the model was further examined in 28 individuals with IGT identified in the same 60 families. Before participation in the study, all individuals provided informed consent. The study was approved by the Ethical Committee of Copenhagen and was in accordance with the principles of the Declaration of Helsinki.

OGTT

All individuals underwent a standardized and extended 75-g frequently sampled OGTT. After a 12-h overnight fast, venous blood samples were drawn in triplicate at −10, −5, and 0 min before the OGTT and at 10, 20, 30, 40, 50, 60, 75, 90, 105, 120, 140, 160, 180, 210, and 240 min from the start of the glucose load for analysis of plasma glucose and serum insulin levels. The plasma glucose concentration was analyzed by a glucose oxidase method (Granutest; Merck, Darmstadt, Germany). Serum insulin was determined by enzyme-linked immunoadsorbent assay with a narrow specificity excluding des(31,32)-proinsulin and intact proinsulin (DAKO Diagnostics, Ely, U.K.) (14).

IVGTT

All individuals underwent a 33-point tolbutamide-modified, frequently sampled IVGTT (13) within 1 week after the OGTT examination except for a few individuals who underwent an IVGTT within 4 weeks. The SI was calculated using the Bergman MINMOD computer program (15). The glucose-induced serum AIRinsulin 0–8 min was calculated as the incremental areas under the curves from 0 to 8 min.

Individuals for external validation

Twenty-eight nondiabetic individuals without IGT, randomly chosen from participants in a population-based study at the Research Centre for Prevention and Health (RCPH) of 695 individuals born in 1936 (16), were examined by both an OGTT and an IVGTT. An extended 75-g OGTT was performed after a 10-h overnight fast. Blood samples were drawn in duplicate between 7:45 and 10:00 a.m. before the oral glucose load, i.e., at −5 and 0 min and at 15, 30, 45, 60, 90, 120, and 180 min after the glucose load. Plasma glucose levels were analyzed at the RCPH using a glucose oxidase method (17). Serum insulin was analyzed at Steno Diabetes Center (14). The IVGTT was performed at Steno Diabetes Center by the protocol described above (13).

Anthropometric measurements

Body weight (with light clothing) was measured to the nearest 0.1 kg and height (without shoes) was estimated to the nearest 0.5 cm. BMI was calculated as weight in kilograms divided by the square of height in meters. Waist circumference (to the nearest centimeter, individuals without clothes) was measured midway between the lowest rib and the iliac crest on standing subjects. Hip circumference (to the nearest centimeter with individuals in underwear) was measured over the widest part of the gluteal region. Fat mass was measured using a bioelectrical impedance method (18).

Statistical methods

An empirical data-driven approach was chosen, using multiple linear regression to derive predictive equations of log(SI) and log(AIR), i.e., the natural logarithm. Demographic data and glucose and insulin concentrations during the OGTT were used as independent variables in the analysis. To adjust for within-family correlation, a random family factor was added to the models. An a priori analysis strategy was formulated to ensure efficient exploitation of the data. The models were based on untransformed and transformed glucose and insulin results (square and reciprocal transformation) and standardized areas under the concentration curves for plasma glucose and serum insulin, defined as the area under the curve, above baseline from time 0 to time t minutes divided by t. The demographic factors included age, sex, height, body weight, waist circumference, hip circumference, fat mass, BMI, waist-to-hip ratio, and fat mass-to-body weight ratio.

Of the total data, ∼75% were randomized (stratified according to age and missing data status) to an estimation sample used for predicting log(SI) and log(AIR). The remaining 25% of the data were considered as an internal validation sample for assessment of the accuracy of the predictive equations, i.e., a cross validation. Furthermore, external validation was provided by the application of the predictive models to the data from the RCPH.

A combination of backwards elimination and forward selection was chosen in the modeling phase to handle the large number of variables in each model. A model was initially based on plasma glucose and serum insulin levels at 0, 30, 60, 90, 120, and 180 min as regression variables to describe the established indexes of insulin sensitivity and β-cell function. Depending on which of these variables was statistically significant at a 10% significance level, values at adjacent time points were added sequentially to the model. We have thus used plasma glucose and serum insulin responses from several time points during the OGTT to generate the optimal equations for OGTT-derived indexes of insulin sensitivity (BIGTT-SI|full) and β-cell function (BIGTT-AIRfull). Also, we generated and tested simple indexes of SI and AIR using time points that are routinely measured in most metabolic, genetic, and epidemiological studies, i.e., at 0, 30, and 120 min (BIGTT-SI|0-30-120 and BIGTT-AIR0-30-120), and 0, 60, and 120 min (BIGTT-SI|0-60-120 and BIGTT-AIR0-60-120), respectively.

Evaluations and comparisons between models were based on the residual SD and the correlation coefficient (R2) obtained from the regressions. R2 describes the degree of variation explained by the model relative to the total variation in the population subjected to analysis. Because R2 is population dependent, it can only be used for comparisons of models within a dataset, not between datasets. However, the SD is comparable between models applied to various datasets, as the SD on the log scale corresponds approximately to the coefficient of variation of the predicted SI and AIR on the original scale.

Calculations of insulin sensitivity and acute insulin response using previously published models

Formulas from previously published models were applied to the present datasets to compare the accuracy of the different models (Table 3). As previously described models were not based on log-transformed measures of insulin sensitivity and β-cell function, the accuracy has been assessed after performance of an adjustment based on a regression analysis of the log-transformed result of each formula, measuring concordance with the log(SI) and log(AIR) estimating an intercept based on the estimation dataset. Thus, the risk of performing an unfair comparison with the BIGTT models is eliminated, because additional corrections to the data are obtained by the adjustment.

RESULTS—

Characteristics of participants are given in Table 1. Table 2 shows the predictive equations that were generated for calculations of BIGTT-SI and BIGTT-AIR. Estimates of SI (BIGTT-SI|full) and AIR (BIGTT-AIRfull) were highly correlated to IVGTT-derived values of SI (R2 = 0.77) and AIR (R2 = 0.54) (Table 3).

Each of the OGTT-derived estimates of SI was compared to estimates of SI obtained in the internal and external validation dataset as well as to estimates of insulin sensitivity using the fasting insulin level, the homeostasis model assessment (HOMA), and four other previously published models (Table 3). On the basis of the SD of the estimates, both the full model (BIGTT-SI|full) and the two more simple models (BIGTT-SI|0-30-120 and BIGTT-SI|0-60-120) for estimation of SI had an ∼30% higher accuracy than two widely used simple indexes of insulin sensitivity, i.e., fasting insulin and HOMA (Table 3). The OGTT-derived estimates of SI were almost similar in the two validation datasets (Table 3). The relationship between SI obtained from the IVGTT and BIGTT-SI|0-60-120 is presented in Fig. 1A, which shows a high degree of correlation at all levels of insulin sensitivity. A similar correlation at all levels of insulin sensitivity is seen by applying the optimal model (BIGTT-SI|full) as well as the BIGTT-SI|0-30-120 (data not shown).

The SD and R2 for various indexes of β-cell function are also shown in Table 3. The novel BIGTT-AIR methods are about 20–30% more accurate than three currently used models for estimation of β-cell function, and the estimates were very similar in the two validation datasets (Table 3). The relationship between β-cell function estimated by the IVGTT and by the BIGTT-AIR0-60-120 is shown in Fig. 1B.

For subjects with IGT, the BIGTT models for the estimation of indexes of insulin sensitivity and β-cell function were less accurate than when they were applied to data from nondiabetic individuals without IGT (see Table 1 of the online appendix available at http://dx.doi.org/10.2337/dc06-1240). This was a general observation for all applied models. However, the Matsuda, Cederholm, and Belfiori indexes did seem to capture the insulin sensitivity for subjects with IGT in a more satisfactory manner than the BIGTT model. Regarding the indexes of β-cell function, the BIGTT model was more accurate than the alternative models (see Table 1 of the online appendix).

CONCLUSIONS—

We present novel and validated models for calculation of SI and AIR with data available from an OGTT. The models are developed for accurate measurement of SI and AIR in nondiabetic individuals without IGT. The plasma glucose level obtained at 120 min after the ingestion of the glucose load identifies individuals for whom the method is applicable and at the same time identifies individuals having IGT or overt diabetes. Patients with type 2 diabetes and IGT are characterized by various degrees of abnormalities in both insulin action and insulin secretion (19), and it is therefore unlikely that models for measurements of insulin sensitivity and β-cell function derived from an OGTT could be accurate throughout the whole spectrum of glucose tolerance (20). As expected, our model did not work as well in individuals with IGT (see Table 1 of the online appendix). If detailed information on β-cell function and/or insulin sensitivity is essential in these individuals, other methods have to be used in addition to the OGTT. All three BIGTT-SI models were highly positively correlated (R2 = 0.69–0.77) to the SI derived from an IVGTT. This was the case for both the estimation dataset and the validation datasets. As correlation coefficients should not be used for comparisons between studies, we also report the residual SD of log(SI) for the various models derived from the present dataset. We find that all of our three models provide more accurate estimates of insulin sensitivity than various previously published methods (7–12). The higher accuracy of the present models might be due to 1) the fact that the models were developed using detailed data from a relatively large study population (n = 194), 2) only data from nondiabetic individuals without IGT were used for model development to avoid the confounding effect of overt hyperglycemia on estimates of insulin secretion and action, and 3) the fact that information on sex and BMI were included. It is noteworthy that for log(SI) the estimated parameters for sex and BMI show a high degree of consistency among the different models, indicating that adjustment for these factors is indeed relevant. However, adding information about sex and BMI to previously used indexes did not improve their accuracy.

In the present study we have chosen to use insulin sensitivity estimates from a frequently sampled IVGTT as reference for the BIGTT-SI models. Most other published OGTT-derived models for estimation of insulin sensitivity are developed on the basis of data from euglycemic-hyperinsulinemic clamp studies. We believe, however, that our models provide an estimate of insulin sensitivity that could be compared with clamp data, as previous reports have shown a strong positive correlation between SI obtained from the frequently sampled IVGTT and SI obtained from the euglycemic-hyperinsulinemic clamp in normoglycemic individuals (5,21).

The models derived from OGTT data for measurement of β-cell function were developed with the AIR0–8 min response from the IVGTT, which is the gold standard, as reference. The models are highly accurate compared with other available methods using OGTT data for calculation of insulin secretion (Table 3) (9,12,22–26). Both our models and other models for measurement of β-cell function were less accurate when applied to individuals with IGT, but the BIGTT model was still more accurate than the alternative models (see Table 1 of the online appendix). Adding information on sex, height, and weight to previously used indexes did not improve their accuracy.

In contrast to anthropometric variables, which are reproducible among laboratories, assay characteristics for measurement of serum insulin such as linearity, recovery, accuracy, precision, and cross-reactivity to proinsulin and its primary conversion intermediates vary among laboratories (27). In the present model we have used an insulin assay with no cross-reactivity to proinsulin and its primary conversion intermediates (14). Whether our model is valid when serum insulin levels are analyzed by other assays remains to be studied.

In summary, we have developed and validated novel models for assessment of OGTT-derived estimates of SI and AIR. Information on sex and BMI combined with analysis of plasma glucose and serum insulin levels in the fasting state and up to eight time points during 4 h (full models) provides indexes for SI and AIR that are highly correlated to indexes obtained from a frequently sampled IVGTT. Furthermore, we have validated more simple OGTT-based models that can be used to predict estimates of SI and AIR, incorporating information on sex, BMI, and measurement of plasma glucose and serum insulin levels at 0, 30, 60, and 120 min. The models are designed for nondiabetic individuals without IGT; glucose tolerance is also being estimated from the OGTT. Because of the simplicity of these models, they can be implemented in large scale metabolic, genetic, and epidemiological studies.

Figure 1—
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1—

A: Relationship between SI obtained from an IVGTT [known log(SI)] and SI obtained from OGTT-based data from plasma glucose and serum insulin levels at t = 0, 60, and 120 min; sex; and BMI [predicted log (BIGTT-SI|0-60-120)]. Triangles depict data from the estimation sample; circles and squares depict data from the internal and external validation samples, respectively. B: Relationship between serum AIR during 0–8 min obtained from an IVGTT [known log(AIR)] and AIR obtained from OGTT-based data using information from plasma glucose and serum insulin levels at t = 0, 60, and 120 min; sex; and BMI [predicted log(BIGTT-AIR0-60-120)]. Triangles depict data from the estimation sample; circles and squares depict data from the internal and external validation samples, respectively.

View this table:
  • View inline
  • View popup
Table 1—

Clinical and biochemical data for 258 nondiabetic individuals without IGT used for model development and internal validation and for 28 nondiabetic individuals without IGT for external validation

View this table:
  • View inline
  • View popup
Table 2—

OGTT-derived models for calculations of SI and AIR in nondiabetic individuals without IGT

View this table:
  • View inline
  • View popup
Table 3—

SD and R2 for various indices of the SI compared with the SI as estimated from an IVGTT and indices of β-cell function compared with AIR as calculated from an IVGTT

Acknowledgments

This study was supported by grants from the Danish Medical Research Council, the European Union (BMH4-CT98-3084 and QLK-CT-200-01038), the Velux Foundation, the Danish Diabetes Association, and The Danish Heart Foundation.

We thank the participants who took part in the studies and the staff at the Steno Diabetes Center and Research Centre for Prevention and Health.

Footnotes

  • T.H. and T.D. contributed equally to this work.

    Additional information for this article can be found in an online appendix at http://dx.doi.org/10.2337/dc06-1240.

    A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

    The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C Section 1734 solely to indicate this fact.

    • Accepted October 19, 2006.
    • Received June 15, 2006.
  • DIABETES CARE

References

  1. ↵
    Andres R, Swerdloff T, Pozefsky T, Coleman D: Manual feedback technique for the control of blood glucose concentration. In Automation in Analytical Chemistry. Skeggs LTJ, Ed. New York, Mediad, 1966, p. 486–491
  2. ↵
    DeFronzo RA: Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev 177–269, 1997
  3. ↵
    Ferrannini E, Mari A: How to measure insulin sensitivity. J Hypertens 16: 895–906, 1998
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    Bergman RN, Ider YZ, Bowden CR, Cobelli C: Quantitative estimation of insulin sensitivity. Am J Physiol 236: E667–E677, 1979
  5. ↵
    Bergman RN, Prager R, Volund A, Olefsky JM: Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J Clin Invest 79: 790–800, 1987
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    Hollenbeck CB, Chen N, Chen YD, Reaven GM: Relationship between the plasma insulin response to oral glucose and insulin-stimulated glucose utilization in normal subjects. Diabetes 33: 460–463, 1984
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Belfiore F, Iannello S, Volpicelli G: Insulin sensitivity indices calculated from basal and OGTT-induced insulin, glucose, and FFA levels. Mol Genet Metab 63: 134–141, 1998
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    Matsuda M, DeFronzo RA: Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22: 1462–1470, 1999
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412–419, 1985
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Jarvinen H, Van Haeften T, Renn W, Gerich J: Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 23: 295–301, 2000
    OpenUrlAbstract
  11. ↵
    Cederholm J, Wibell L: Insulin release and peripheral sensitivity at the oral glucose tolerance test. Diabetes Res Clin Pract 10: 167–175, 1990
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    Wareham NJ, Phillips DI, Byrne CD, Hales CN: The 30 minute insulin incremental response in an oral glucose tolerance test as a measure of insulin secretion. Diabet Med 12: 931, 1995
    OpenUrlCrossRefPubMed
  13. ↵
    Hansen T, Ambye L, Grarup N, Hansen L, Echwald SM, Ferrer J, Pedersen O: Genetic variability of the SUR1 promoter in relation to β-cell function and type II diabetes mellitus. Diabetologia 44: 1330–1334, 2001
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    Andersen L, Dinesen B, Jorgensen PN, Poulsen F, Roder ME: Enzyme immunoassay for intact human insulin in serum or plasma. Clin Chem 39: 578–582, 1993
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Pacini G, Bergman RN: MINMOD: a computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance test. Comput Methods Programs Biomed 23: 113–122, 1986
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    Drivsholm T, Ibsen H, Schroll M, Davidsen M, Borch-Johnsen K: Increasing prevalence of diabetes mellitus and impaired glucose tolerance among 60-year-old Danes. Diabet Med 18: 126–132, 2001
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    Kadish AH, Little RL, Sternberg JC: A new and rapid method for the determination of glucose by measurement of rate of oxygen consumption. Clin Chem 14: 116–131, 1968
    OpenUrl
  18. ↵
    Heitmann BL: Prediction of body water and fat in adult Danes from measurement of electrical impedance: a validation study. Int J Obes 14: 789–802, 1990
    OpenUrlPubMedWeb of Science
  19. ↵
    Laakso M: How good a marker is insulin level for insulin resistance? Am J Epidemiol 137: 959–965, 1993
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Groop LC, Widen E, Ferrannini E: Insulin resistance and insulin deficiency in the pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus: errors of metabolism or of methods? Diabetologia 36: 1326–1331, 1993
    OpenUrlCrossRefPubMedWeb of Science
  21. ↵
    Beard JC, Bergman RN, Ward WK, Porte DJ: The insulin sensitivity index in nondiabetic man: correlation between clamp-derived and IVGTT-derived values. Diabetes 35: 362–369, 1986
    OpenUrlAbstract/FREE Full Text
  22. ↵
    Kadowaki T, Miyake Y, Hagura R, Akanuma Y, Kajinuma H, Kuzuya N, Takaku F, Kosaka K: Risk factors for worsening to diabetes in subjects with impaired glucose tolerance. Diabetologia 26: 44–49, 1984
    OpenUrlPubMedWeb of Science
  23. Byrne CD, Wareham NJ, Brown DC, Clark PM, Cox LJ, Day NE, Palmer CR, Wang TW, Williams DR, Hales CN: Hypertriglyceridaemia in subjects with normal and abnormal glucose tolerance: relative contributions of insulin secretion, insulin resistance and suppression of plasma non-esterified fatty acids. Diabetologia 37: 889–896, 1994
    OpenUrlPubMed
  24. Efendic S, Luft R, Wajngot A: Aspects of the pathogenesis of type 2 diabetes. Endocr Rev 5: 395–410, 1984
    OpenUrlCrossRefPubMedWeb of Science
  25. Kosaka K, Hagura R, Kuzuya T: Insulin responses in equivocal and definite diabetes, with special reference to subjects who had mild glucose intolerance but later developed definite diabetes. Diabetes 26: 944–952, 1977
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Phillips DI, Clark PM, Hales CN, Osmond C: Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabet Med 11: 286–292, 1994
    OpenUrlCrossRefPubMedWeb of Science
  27. ↵
    Robbins DC, Andersen L, Bowsher R, Chance R, Dinesen B, Frank B, Gingerich R, Goldstein D, Widemeyer HM, Haffner S, Hales CN, Jarett L, Polonsky K, Porte D, Skyler J, Webb G, Gallagher K: Report of the American Diabetes Association’s Task Force on standardization of the insulin assay. Diabetes 45: 242–256, 1996
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Diabetes Care: 30 (2)

In this Issue

February 2007, 30(2)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The BIGTT Test
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The BIGTT Test
Torben Hansen, Thomas Drivsholm, Søren A. Urhammer, Rene T. Palacios, Aage Vølund, Knut Borch-Johnsen, Oluf Pedersen
Diabetes Care Feb 2007, 30 (2) 257-262; DOI: 10.2337/dc06-1240

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

The BIGTT Test
Torben Hansen, Thomas Drivsholm, Søren A. Urhammer, Rene T. Palacios, Aage Vølund, Knut Borch-Johnsen, Oluf Pedersen
Diabetes Care Feb 2007, 30 (2) 257-262; DOI: 10.2337/dc06-1240
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • RESEARCH DESIGN AND METHODS
    • RESULTS—
    • CONCLUSIONS—
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Suppl Material
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Diagnosis of Neuropathy and Risk Factors for Corneal Nerve Loss in Type 1 and Type 2 Diabetes: A Corneal Confocal Microscopy Study
  • Plasma Methylglyoxal Levels Are Associated With Amputations and Mortality in Severe Limb Ischemia Patients With and Without Diabetes
  • Intensive Risk Factor Management and Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: The ACCORD Trial
Show more Pathophysiology/Complications

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.